In 2004, Avastin® (bevacizumab), a humanized anti-VEGF monoclonal antibody, was the first angiogenesis inhibitor approved by the U.S. Food and Drug Administration for the treatment of colorectal cancer. The gene discussed is VEGFA; the disease is colorectal cancer.